
## PARAGON-HF #ESCCongress



**Trial Description:** Patients with heart failure with preserved ejection fraction were randomized to sacubitril-valsartan 97/103 mg twice daily versus valsartan 160 mg twice daily.



## **RESULTS**

- Primary efficacy endpoint: rate of cardiovascular deaths or hospitalizations for heart failure was 12.8 events per 100 patient-years in the sacubitril-valsartan group vs. 14.6 events per 100 patient-years in the valsartan group (p = NS)
- NYHA class improvement: 15.0% in the sacubitril-valsartan group vs. 12.6% in the valsartan group (p < 0.05)

## **CONCLUSIONS**

 Among patients with heart failure with preserved ejection fraction, sacubitrilvalsartan was not effective at reducing the incidence of cardiovascular death or hospitalization for heart failure compared with valsartan

Solomon SD, et al. N Engl J Med 2019; Sep 1: [Epub]